CY1119906T1 - Πολυμερικεσ συζευξεισ οπιοειδων ανταγωνιστων - Google Patents

Πολυμερικεσ συζευξεισ οπιοειδων ανταγωνιστων

Info

Publication number
CY1119906T1
CY1119906T1 CY20181100170T CY181100170T CY1119906T1 CY 1119906 T1 CY1119906 T1 CY 1119906T1 CY 20181100170 T CY20181100170 T CY 20181100170T CY 181100170 T CY181100170 T CY 181100170T CY 1119906 T1 CY1119906 T1 CY 1119906T1
Authority
CY
Cyprus
Prior art keywords
opioid antagonist
polymerikes
syzefxeis
opioid
polymer
Prior art date
Application number
CY20181100170T
Other languages
English (en)
Inventor
Michael David Bentley
Michael James Roberts
Xiaoming Shen
Lin Cheng
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US33040001P priority Critical
Priority to PCT/US2002/033325 priority patent/WO2003032990A2/en
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CY1119906T1 publication Critical patent/CY1119906T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

Η παρούσα εφεύρεση παρέχει πολυμερικές συζεύξεις οπιοειδών ανταγωνιστών που περιλαμβάνουν ένα πολυμερές όπως είναι η πολυ(αιθυλενογλυκόλη), ομοιοπολικά προσκολλημένες σε έναν οπιοειδή ανταγωνιστή. Η σύνδεση μεταξύ του πολυμερούς και του οπιοειδούς ανταγωνιστή είναι κατά προτίμηση υδρολυτικά σταθερή. Η εφεύρεση παρέχει επίσης μια μέθοδο για τη θεραπεία μιας ή περισσότερων παρενεργειών που σχετίζονται με τη χρήση οπιοειδών αναλγητικών, όπως είναι η δυσκοιλιότητα, η ναυτία ή ο κνησμός, με τη χορήγηση πολυμερικών συζεύξεων της εφεύρεσης.
CY20181100170T 2001-10-18 2018-02-12 Πολυμερικεσ συζευξεισ οπιοειδων ανταγωνιστων CY1119906T1 (el)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33040001P true 2001-10-18 2001-10-18
PCT/US2002/033325 WO2003032990A2 (en) 2001-10-18 2002-10-18 Polymer conjugates of opioid antagonists

Publications (1)

Publication Number Publication Date
CY1119906T1 true CY1119906T1 (el) 2018-06-27

Family

ID=23289594

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100170T CY1119906T1 (el) 2001-10-18 2018-02-12 Πολυμερικεσ συζευξεισ οπιοειδων ανταγωνιστων

Country Status (15)

Country Link
US (4) US7056500B2 (el)
EP (3) EP2236161A1 (el)
JP (2) JP4814488B2 (el)
KR (2) KR101009309B1 (el)
AU (1) AU2002360284B2 (el)
CA (1) CA2463938C (el)
CY (1) CY1119906T1 (el)
DK (2) DK2939696T3 (el)
ES (2) ES2654819T3 (el)
HK (1) HK1215171A1 (el)
LT (1) LT1436012T (el)
MX (1) MXPA04003597A (el)
PT (2) PT2939696E (el)
SI (2) SI1436012T1 (el)
WO (1) WO2003032990A2 (el)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
CA2385533C (en) 1999-10-04 2008-03-25 Shearwater Corporation Polymer stabilized neuropeptides
PT2939696E (pt) 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
EP3025726B1 (en) * 2002-01-18 2019-11-20 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
WO2004091622A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
PT2368554E (pt) * 2003-04-08 2015-02-06 Progenics Pharm Inc Formulações farmacêuticas que contêm metilnaltrexona
EP1638607A1 (en) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
AU2014280956B2 (en) * 2003-12-16 2016-09-22 Nektar Therapeutics Chemically modified small molecules
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PT1694363E (pt) * 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
JP2007530569A (ja) * 2004-03-23 2007-11-01 アムジエン・インコーポレーテツド 化学修飾タンパク質組成物及び方法
US7495098B2 (en) * 2004-06-08 2009-02-24 Mallinckrodt Inc Extraction of alkaloids from opium
JPWO2006064780A1 (ja) * 2004-12-14 2008-06-12 塩野義製薬株式会社 便秘治療剤
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
JP5241484B2 (ja) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2007240680B2 (en) 2006-04-21 2013-05-02 Nektar Therapeutics Stereoselective reduction of a morphinone
US20110105381A2 (en) * 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
JP5371746B2 (ja) 2006-05-26 2013-12-18 ファーマコフォア, インコーポレイテッド フェノール性オピオイドの制御放出
AU2007317788B2 (en) * 2006-11-07 2013-05-02 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist
EP2101773A2 (en) * 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
CN101686687A (zh) * 2007-02-28 2010-03-31 塞瑞纳治疗公司 活化的聚噁唑啉及包含该聚噁唑啉的组合物
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
KR101568428B1 (ko) * 2007-03-12 2015-11-11 넥타르 테라퓨틱스 올리고머―오피오이드 효능제 컨주게이트
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PL2139890T3 (pl) 2007-03-29 2014-11-28 Wyeth Llc Antagoniści obwodowych receptorów opioidowych i ich zastosowania
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
ES2620373T3 (es) 2008-07-01 2017-06-28 University Of Chicago Partículas que contienen un antagonista del receptor de opioides periférico
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
DE102010049607A1 (de) 2009-10-26 2011-06-30 Becker, Claus, Prof., 76470 Konjugate von Nukleotiden und Methoden zu deren Anwendung
CN107308125A (zh) 2010-03-11 2017-11-03 惠氏有限责任公司 甲基纳曲酮的口服制剂和亲脂盐
PE20140636A1 (es) 2010-09-30 2014-06-18 Astrazeneca Ab Conjugado de naloxol-peg cristalino
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
US20130338175A1 (en) 2010-12-21 2013-12-19 Nektar Therapeutics Multi-Arm Polymeric Prodrug Conjugates of Pemetrexed-Based Compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20130345298A1 (en) 2010-12-22 2013-12-26 Nektar Therapeutics Multi-Arm Polymeric Prodrug Conjugates of Cabazitaxel-Based Compounds
CN103906522B (zh) * 2011-11-07 2017-04-12 尼克塔治疗公司 阿片激动剂化合物和止痛化合物的组合物、剂型以及共给药
WO2014043110A2 (en) * 2012-09-11 2014-03-20 University Of Massachusetts Crosslinked polymer nano-assemblies and uses thereof
CA2886276A1 (en) 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015253417A1 (en) 2014-04-28 2016-10-27 Orphomed, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064914A1 (en) * 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10226456B2 (en) * 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
CN107033154A (zh) * 2016-02-02 2017-08-11 苏州派格生物科技有限公司 阿片受体拮抗剂缀合物及其应用
WO2017143126A1 (en) * 2016-02-18 2017-08-24 Virginia Commonwealth University Nanoparticle conjugated synthetic opioid prodrugs and methods of their use
CN108210933A (zh) * 2016-12-22 2018-06-29 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
WO2019018638A1 (en) * 2017-07-20 2019-01-24 Suzhou Runxindatai Pharmaceutics Ltd Co. Abuse-resistant long-acting release opioid prodrugs

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (el) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y., Us
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4864781A (en) * 1981-06-17 1989-09-12 Emblin Robert T Multiple panel metal roofing system with overlapping panel edges
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
FR2514644B1 (el) * 1981-10-19 1984-04-20 Sanofi Sa
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
DE69030829D1 (de) 1989-03-10 1997-07-10 Hoffmann La Roche Reagenzien zum Nachweis von Drogen
JPH0383914A (en) 1989-08-18 1991-04-09 W R Grace & Co Drug carrier
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5250542A (en) 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US5270328A (en) 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
ES2122261T3 (es) 1993-03-17 1998-12-16 Minnesota Mining & Mfg Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5434171A (en) 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP0914097B1 (en) 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
EP2266564B1 (en) * 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
PT1411075E (pt) 1998-03-12 2008-08-05 Nektar Therapeutics Al Corp Método para a preparação de conjugados de polímeros
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP2003522146A (ja) * 2000-02-08 2003-07-22 ユーロ−セルティーク,エス.エイ. 外圧に抵抗性の経口オピオイドアゴニスト製剤
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
WO2001068080A2 (en) * 2000-03-15 2001-09-20 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
WO2002043772A2 (en) 2000-11-30 2002-06-06 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
AU2002251988A1 (en) 2001-02-20 2002-09-04 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
PT2939696E (pt) 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
EP1441772A2 (en) 2001-10-29 2004-08-04 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
WO2003037385A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
AU2002351388A1 (en) 2001-12-14 2003-06-30 The University Of Wyoming Methods and compositions for controlled release of drugs
WO2004082620A2 (en) 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PT1694363E (pt) * 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
AU2007240680B2 (en) 2006-04-21 2013-05-02 Nektar Therapeutics Stereoselective reduction of a morphinone
AU2007317788B2 (en) * 2006-11-07 2013-05-02 Nektar Therapeutics Dosage forms and co-administration of an opioid agonist and an opioid antagonist
EP3064198A1 (en) * 2007-09-03 2016-09-07 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
KR20170121368A (ko) 2016-04-22 2017-11-02 삼성디스플레이 주식회사 투명 전도막 및 이를 포함하는 전자 소자

Also Published As

Publication number Publication date
KR101009309B1 (ko) 2011-01-18
JP4814488B2 (ja) 2011-11-16
JP2005506351A (ja) 2005-03-03
PT1436012T (pt) 2018-03-27
US20030124086A1 (en) 2003-07-03
SI2939696T1 (sl) 2016-06-30
LT1436012T (lt) 2018-04-10
EP2939696B1 (en) 2016-03-09
US7662365B2 (en) 2010-02-16
EP2939696A1 (en) 2015-11-04
PT2939696E (pt) 2016-06-17
KR20050037423A (ko) 2005-04-21
US20100105715A1 (en) 2010-04-29
ES2654819T3 (es) 2018-02-15
MXPA04003597A (es) 2004-07-30
US8617530B2 (en) 2013-12-31
US8349307B2 (en) 2013-01-08
JP5570137B2 (ja) 2014-08-13
DK2939696T3 (en) 2016-05-23
JP2009167214A (ja) 2009-07-30
ES2569262T3 (es) 2016-05-09
AU2002360284B2 (en) 2006-11-02
WO2003032990A3 (en) 2004-02-26
US20130165466A1 (en) 2013-06-27
AU2002360284C1 (en) 2003-04-28
KR20090130155A (ko) 2009-12-17
EP1436012B1 (en) 2017-12-20
CA2463938C (en) 2011-08-09
EP2236161A1 (en) 2010-10-06
HK1215171A1 (zh) 2016-08-19
DK1436012T3 (en) 2018-01-22
CA2463938A1 (en) 2003-04-24
KR100974842B1 (ko) 2010-08-11
SI1436012T1 (en) 2018-03-30
EP1436012A2 (en) 2004-07-14
WO2003032990A2 (en) 2003-04-24
US7056500B2 (en) 2006-06-06
US20060105046A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
Meudtner et al. Responsive Backbones Based on Alternating Triazole‐Pyridine/Benzene Copolymers: From Helically Folding Polymers to Metallosupramolecularly Crosslinked Gels
Stubbs et al. Towards a Universal Polymer Backbone: Design and Synthesis of Polymeric Scaffolds Containing Terminal Hydrogen‐Bonding Recognition Motifs at Each Repeating Unit
DE60203531D1 (de) Molekulare kreuzleitungsverriegelungsvorrichtung
BR9911077A (pt) Polìmeros absorventes de água com moléculas de espaço oco supramoleculares, processos para a sua preparação e seu emprego
CO5080774A1 (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer
DE60115260D1 (de) Niedermolekulare polymerzusätze enthaltende klebstoffe
CY1115589T1 (el) Φαρμακευτικεσ συνθεσεισ για την προληψη και αγωγη των διαταραχων του κεντρικου νευρικου συστηματοσ περιλαμβανοντασ μια νικοτινικη ενωση και εναν αναστολεα ακετυλχολινεστερασησ
CO5290342A1 (es) Conformidad proactiva para pozos de petroleo o de gas
ES2111543T3 (es) Microperlas de polimero organico cargado en el procedimiento de fabricacion de papel.
TR200101858T2 (tr) JNK protein kinaz inhibitörleri olarak 4-ariloksindoller
TR200002015T2 (tr) Protein tirosin kinaz inhibitörleri olarak bisiklik heteroaromatik bileşikler.
CY1113084T1 (xx) ΠΑΡΑΓΩΓΟ ΒΕΝΖΙΜΙΔΑΖΟΛΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΟΥ ΩΣ ΑΝΤΑΓΩΝΙΣΤΟΥ ΤΟΥ ΥΠΟΔΟΧΕΑ aii
CY1107493T1 (xx) Μεθοδοι και συνθεσεισ για την προληψη ανεκτικοτητασ στα βρογχοδιασταλτικα
CY1112214T1 (xx) Ενωσεισ για χρησεισ σχετιζομενεσ με φλεγμονεσ και το ανοσοποιητικο
NO301585B1 (no) Benzimidazoler og legemidler inneholdende disse
CY1108986T1 (xx) Εκχυλισματα κριλ για την προληψη ή/και τη θεραπεια καρδιαγγειακων νοσηματων
TR200200462T2 (tr) Poli(trimetilen tereftalatin) hazırlanışı
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
CY1120816T1 (el) Τοπικη εφαρμογη και διαδερματικη απελευθερωση αλλαντοτοξινων
CY1119349T1 (el) Ομοιοπολικα συζευγματα παραγωγων 1,4-δισ-φαινυλαζο-βενζολιου και φαινυλαζο-φαιναζινησ ωσ σκουροχρωμων αποσβεστων μεταφορασ ενεργειασ δοτη-δεκτη για φθοριζουσα ανιχνευση βιομοριων και φαρμακων
NO20161431A1 (no) Chalicheamicinderivat-bærerkonjugater.
BR9812815A (pt) Composições detergentes para a lavagem de roupas com polìmeros com base em uma amina linear para proporcionar benefìcios de aparência e de integridade aos tecidos lavados com as mesmas
CY1116575T1 (el) Χρησεισ αρωματικου-κατιοντικου πεπτιδιου
CY1110384T1 (xx) Κρυσταλλικη μορφη τησ (r)-2[[[3-μεθυλο-4-(2,2,2-τριφθοροαιθοξυ)-2-πυριδινυλο]μεθυλο]σουλφινυλο]-1η-βενζιμιδαζολησ
CY1107475T1 (xx) Αναστολεισ ρο-κινασησ